Condition
Mediastinal Lymphoma
Total Trials
3
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
1Total
P 1 (1)
Trial Status
Not Yet Recruiting1
Recruiting1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT04613388RecruitingPrimary
Registry Study of Proton Radiotherapy in Lymphoma
NCT03969693Not Yet RecruitingPrimary
Lymphoma Patients Undergoing Mediastinal Radiotherapy in the Era of Modern Chemoradiation
NCT02950220Phase 1Completed
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Showing all 3 trials